Immutep GmbH

General information

Immutep GmbH
Glinkastr. 28
10117 Berlin, Berlin
Germany

Contact person: Claudia Jacoby, Director of Manufacturing
Company main phone: +49 (30) 88716843
Website: https://www.immutep.com/

Source of foundation:	Subsidiary
Name of foundation source:	Immutep Limited

Corporate description / mission:
Immutep is a biopharmaceutical company developing immunotherapeutics in oncology. The company's products include a T cell immunostimulatory factor (APC activator) for cancer chemo-immunotherapy and a therapeutic antibody for immune response modulation in cancer.

State of ownership: Subsidiary
Headquarters: HQ: No

Remarks on ownership / listings
Headquartered at Immutep Limited, Australia.

Formerly Prima BioMed.

Categorization

Sector:

Biotechnology - Therapeutics and Diagnostics

Subsector:

Antibodies
Immunotherapy
Proteins

Primary therapeutic areas:

Infectious and parasitic diseases / infectiology / parasitology
Neoplasms / cancer / oncology

Business model:

Manufacturer
R&D
Subsidiary

Customer segments:

Other
Hospitals
Large biotech & big pharma
Small biotech

Summary Products / Services / Technologies

Description of products:
IMP701, a blocking anti-LAG-3 antibody for cancer
IMP761, an agonist antibody of LAG-3, etc.

Technology used:
LAG-3 Technology